Isoliquiritigenin (ISL) inhibits ErbB3 signaling in prostate cancer cells

Jae In Jung, Eunkyung Chung, Mi Ra Seon, Hyun Kyung Shin, Eun Ji Kim, Soon Sung Lim, WonYoon Chung, Kwang Kyun Park, Jung Han Yoon Park

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Isoliquiritigenin (ISL), a flavonoid found in licorice, shallot, and bean sprouts, has been identified as a potent anti-tumor promoting agent. We previously demonstrated that ISL reduces cell proliferation and induces apoptosis in DU145 human prostate cancer cells and MAT-LyLu (MLL) rat prostate cancer cells. Overexpression of members of the ErbB receptor family is a frequently observed event in several human cancers, and ErbB receptors currently constitute the primary targets of anticancer strategies. In order to elucidate the mechanisms underlying the ISL regulation of prostate cancer cell proliferation, the present study attempted to determine whether ISL inhibits heregulin (HRG)-β-induced ErbB3 signaling. DU145 and MLL cells were cultured in serum-free medium with ISL and/or HRG-β. Exogenous HRG-β alone was shown to effect an increase in the numbers of viable cells, whereas HRG-β did not counteract the ISL-induced growth inhibition. ISL reduced the protein and mRNA levels of ErbB3 in a dose-dependent manner, but exerted no effect on HRG protein levels. Immunoprecipitation/Western blot studies indicated that ISL inhibited the HRG-β-induced tyrosine phosphorylation of ErbB3, the recruitment of the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K) to ErbB3, and Akt phosphorylation in DU145 cells. These results indicate that ISL inhibits the proliferation of prostate cancer cells, at least in part, via the inhibition of ErbB3 signaling and the PI3K/Akt pathway.

Original languageEnglish
Pages (from-to)159-168
Number of pages10
JournalBioFactors
Volume28
Issue number3-4
DOIs
Publication statusPublished - 2006 Jan 1

Fingerprint

Neuregulin-1
Prostatic Neoplasms
Cells
Phosphatidylinositol 3-Kinase
Phosphorylation
Cell proliferation
Shallots
Cell Proliferation
Glycyrrhiza
isoliquiritigenin
Serum-Free Culture Media
Immunoprecipitation
Flavonoids
Tyrosine
Rats
Tumors
Cultured Cells
Neoplasms
Proteins
Cell Count

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Clinical Biochemistry

Cite this

Jung, J. I., Chung, E., Seon, M. R., Shin, H. K., Kim, E. J., Lim, S. S., ... Park, J. H. Y. (2006). Isoliquiritigenin (ISL) inhibits ErbB3 signaling in prostate cancer cells. BioFactors, 28(3-4), 159-168. https://doi.org/10.1002/biof.5520280302
Jung, Jae In ; Chung, Eunkyung ; Seon, Mi Ra ; Shin, Hyun Kyung ; Kim, Eun Ji ; Lim, Soon Sung ; Chung, WonYoon ; Park, Kwang Kyun ; Park, Jung Han Yoon. / Isoliquiritigenin (ISL) inhibits ErbB3 signaling in prostate cancer cells. In: BioFactors. 2006 ; Vol. 28, No. 3-4. pp. 159-168.
@article{f569ee128df9444385871edccee41356,
title = "Isoliquiritigenin (ISL) inhibits ErbB3 signaling in prostate cancer cells",
abstract = "Isoliquiritigenin (ISL), a flavonoid found in licorice, shallot, and bean sprouts, has been identified as a potent anti-tumor promoting agent. We previously demonstrated that ISL reduces cell proliferation and induces apoptosis in DU145 human prostate cancer cells and MAT-LyLu (MLL) rat prostate cancer cells. Overexpression of members of the ErbB receptor family is a frequently observed event in several human cancers, and ErbB receptors currently constitute the primary targets of anticancer strategies. In order to elucidate the mechanisms underlying the ISL regulation of prostate cancer cell proliferation, the present study attempted to determine whether ISL inhibits heregulin (HRG)-β-induced ErbB3 signaling. DU145 and MLL cells were cultured in serum-free medium with ISL and/or HRG-β. Exogenous HRG-β alone was shown to effect an increase in the numbers of viable cells, whereas HRG-β did not counteract the ISL-induced growth inhibition. ISL reduced the protein and mRNA levels of ErbB3 in a dose-dependent manner, but exerted no effect on HRG protein levels. Immunoprecipitation/Western blot studies indicated that ISL inhibited the HRG-β-induced tyrosine phosphorylation of ErbB3, the recruitment of the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K) to ErbB3, and Akt phosphorylation in DU145 cells. These results indicate that ISL inhibits the proliferation of prostate cancer cells, at least in part, via the inhibition of ErbB3 signaling and the PI3K/Akt pathway.",
author = "Jung, {Jae In} and Eunkyung Chung and Seon, {Mi Ra} and Shin, {Hyun Kyung} and Kim, {Eun Ji} and Lim, {Soon Sung} and WonYoon Chung and Park, {Kwang Kyun} and Park, {Jung Han Yoon}",
year = "2006",
month = "1",
day = "1",
doi = "10.1002/biof.5520280302",
language = "English",
volume = "28",
pages = "159--168",
journal = "BioFactors",
issn = "0951-6433",
publisher = "Wiley-Blackwell",
number = "3-4",

}

Jung, JI, Chung, E, Seon, MR, Shin, HK, Kim, EJ, Lim, SS, Chung, W, Park, KK & Park, JHY 2006, 'Isoliquiritigenin (ISL) inhibits ErbB3 signaling in prostate cancer cells', BioFactors, vol. 28, no. 3-4, pp. 159-168. https://doi.org/10.1002/biof.5520280302

Isoliquiritigenin (ISL) inhibits ErbB3 signaling in prostate cancer cells. / Jung, Jae In; Chung, Eunkyung; Seon, Mi Ra; Shin, Hyun Kyung; Kim, Eun Ji; Lim, Soon Sung; Chung, WonYoon; Park, Kwang Kyun; Park, Jung Han Yoon.

In: BioFactors, Vol. 28, No. 3-4, 01.01.2006, p. 159-168.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Isoliquiritigenin (ISL) inhibits ErbB3 signaling in prostate cancer cells

AU - Jung, Jae In

AU - Chung, Eunkyung

AU - Seon, Mi Ra

AU - Shin, Hyun Kyung

AU - Kim, Eun Ji

AU - Lim, Soon Sung

AU - Chung, WonYoon

AU - Park, Kwang Kyun

AU - Park, Jung Han Yoon

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Isoliquiritigenin (ISL), a flavonoid found in licorice, shallot, and bean sprouts, has been identified as a potent anti-tumor promoting agent. We previously demonstrated that ISL reduces cell proliferation and induces apoptosis in DU145 human prostate cancer cells and MAT-LyLu (MLL) rat prostate cancer cells. Overexpression of members of the ErbB receptor family is a frequently observed event in several human cancers, and ErbB receptors currently constitute the primary targets of anticancer strategies. In order to elucidate the mechanisms underlying the ISL regulation of prostate cancer cell proliferation, the present study attempted to determine whether ISL inhibits heregulin (HRG)-β-induced ErbB3 signaling. DU145 and MLL cells were cultured in serum-free medium with ISL and/or HRG-β. Exogenous HRG-β alone was shown to effect an increase in the numbers of viable cells, whereas HRG-β did not counteract the ISL-induced growth inhibition. ISL reduced the protein and mRNA levels of ErbB3 in a dose-dependent manner, but exerted no effect on HRG protein levels. Immunoprecipitation/Western blot studies indicated that ISL inhibited the HRG-β-induced tyrosine phosphorylation of ErbB3, the recruitment of the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K) to ErbB3, and Akt phosphorylation in DU145 cells. These results indicate that ISL inhibits the proliferation of prostate cancer cells, at least in part, via the inhibition of ErbB3 signaling and the PI3K/Akt pathway.

AB - Isoliquiritigenin (ISL), a flavonoid found in licorice, shallot, and bean sprouts, has been identified as a potent anti-tumor promoting agent. We previously demonstrated that ISL reduces cell proliferation and induces apoptosis in DU145 human prostate cancer cells and MAT-LyLu (MLL) rat prostate cancer cells. Overexpression of members of the ErbB receptor family is a frequently observed event in several human cancers, and ErbB receptors currently constitute the primary targets of anticancer strategies. In order to elucidate the mechanisms underlying the ISL regulation of prostate cancer cell proliferation, the present study attempted to determine whether ISL inhibits heregulin (HRG)-β-induced ErbB3 signaling. DU145 and MLL cells were cultured in serum-free medium with ISL and/or HRG-β. Exogenous HRG-β alone was shown to effect an increase in the numbers of viable cells, whereas HRG-β did not counteract the ISL-induced growth inhibition. ISL reduced the protein and mRNA levels of ErbB3 in a dose-dependent manner, but exerted no effect on HRG protein levels. Immunoprecipitation/Western blot studies indicated that ISL inhibited the HRG-β-induced tyrosine phosphorylation of ErbB3, the recruitment of the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3K) to ErbB3, and Akt phosphorylation in DU145 cells. These results indicate that ISL inhibits the proliferation of prostate cancer cells, at least in part, via the inhibition of ErbB3 signaling and the PI3K/Akt pathway.

UR - http://www.scopus.com/inward/record.url?scp=34250353135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250353135&partnerID=8YFLogxK

U2 - 10.1002/biof.5520280302

DO - 10.1002/biof.5520280302

M3 - Article

VL - 28

SP - 159

EP - 168

JO - BioFactors

JF - BioFactors

SN - 0951-6433

IS - 3-4

ER -

Jung JI, Chung E, Seon MR, Shin HK, Kim EJ, Lim SS et al. Isoliquiritigenin (ISL) inhibits ErbB3 signaling in prostate cancer cells. BioFactors. 2006 Jan 1;28(3-4):159-168. https://doi.org/10.1002/biof.5520280302